Literature DB >> 7736372

Periodic health examination, 1995 update: 3. Screening for visual problems among elderly patients. Canadian Task Force on the Periodic Health Examination.

.   

Abstract

OBJECTIVE: To provide recommendations to family physicians for screening elderly patients (over 65 years of age) for visual impairment and its common clinical causes. OPTIONS: Visual acuity screening with Snellen sight chart, funduscopy, retinal photography, tonometry and perimetry. OUTCOMES: Delay or prevention of visual deterioration or blindness. EVIDENCE: A MEDLINE search for relevant articles published between January 1986 and December 1993 was undertaken, the bibliographies of the articles were scrutinized for additional articles, and experts were consulted. The highest available level of evidence was used in making recommendations. VALUES: The evidence-based methods and values of the Canadian Task Force on the Periodic Health Examination were used. Preservation of vision was given the highest value in accordance with other guidelines regarding eyesight. BENEFITS, HARMS AND COSTS: Potential benefits are to maintain or improve visual acuity. Potential for harm to patients is minimal. Limited data are available on costs. RECOMMENDATIONS: There is fair evidence to include in the periodic health examination visual acuity testing with a Snellen sight chart and funduscopy or retinal photography in elderly patients with diabetes of at least 5 years' duration (grade B recommendation). The place of funduscopy in the detection of age-related macular degeneration and glaucomatous changes is controversial. For patients at high risk for glaucoma (positive family history, black race, severe myopia or diabetes) it would be prudent to have a periodic assessment by an ophthalmologist. VALIDATION: Recommendations differ from those of the American Academy of Ophthalmology and the American Optometric Association. Recommendations for glaucoma screening are similar to those of the US Preventive Services Task Force. Present recommendations have been reviewed by experts in ophthalmology and optometry. SPONSOR: These guidelines were developed and endorsed by the task force, which is funded by Health Canada and the National Health Research and Development Program. The principal author (C.P.) was supported in part by the Educational Centre for Aging and Health, McMaster University, Hamilton, Ont.

Entities:  

Mesh:

Year:  1995        PMID: 7736372      PMCID: PMC1337809     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  65 in total

1.  Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration.

Authors:  S B Bressler; N M Bressler; S L Fine; A Hillis; R P Murphy; R J Olk; A Patz
Journal:  Am J Ophthalmol       Date:  1982-02       Impact factor: 5.258

2.  A modified Amsler grid. A self-assessment test for patients with macular disease.

Authors:  L A Yannuzzi
Journal:  Ophthalmology       Date:  1982-02       Impact factor: 12.079

3.  Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects.

Authors:  M F Armaly; D E Krueger; L Maunder; B Becker; J Hetherington; A E Kolker; R Z Levene; A E Maumenee; I P Pollack; R N Shaffer
Journal:  Arch Ophthalmol       Date:  1980-12

4.  Posterior chamber intraocular lens implantation by ophthalmology residents. A prospective study of cataract surgery.

Authors:  B R Straatsma; K T Meyer; J V Bastek; D O Lightfoot
Journal:  Ophthalmology       Date:  1983-04       Impact factor: 12.079

5.  Diagnosis of diabetic eye disease.

Authors:  E J Sussman; W G Tsiaras; K A Soper
Journal:  JAMA       Date:  1982-06-18       Impact factor: 56.272

6.  Validity of a survey question as a measure of visual acuity impairment.

Authors:  R Hiller; D E Krueger
Journal:  Am J Public Health       Date:  1983-01       Impact factor: 9.308

Review 7.  Senile macular degeneration: review of epidemiologic features.

Authors:  F L Ferris
Journal:  Am J Epidemiol       Date:  1983-08       Impact factor: 4.897

8.  The prevalence of glaucoma.

Authors:  B Bengtsson
Journal:  Br J Ophthalmol       Date:  1981-01       Impact factor: 4.638

9.  Optic disc evaluation versus the visual field in chronic glaucoma.

Authors:  C Holmin
Journal:  Acta Ophthalmol (Copenh)       Date:  1982-04

10.  Outcome of cataract surgery I. A prospective, observational study.

Authors:  P Bernth-Petersen
Journal:  Acta Ophthalmol (Copenh)       Date:  1982-04
View more
  6 in total

1.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

Review 2.  Chronic open-angle glaucoma. Review for primary care physicians.

Authors:  Feisal A Adatia; Karim F Damji
Journal:  Can Fam Physician       Date:  2005-09       Impact factor: 3.275

3.  Screening for impaired vision in community-dwelling adults aged 65 years and older in primary care settings.

Authors:  Brenda J Wilson; Susan Courage; Maria Bacchus; James A Dickinson; Scott Klarenbach; Alejandra Jaramillo Garcia; Nicki Sims-Jones; Brett D Thombs
Journal:  CMAJ       Date:  2018-05-14       Impact factor: 8.262

Review 4.  Age-related macular degeneration: cost-of-illness issues.

Authors:  C Oneill; J Jamison; D McCulloch; D Smith
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

5.  Routine eye examinations for persons 20-64 years of age: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-07-01

Review 6.  Travoprost.

Authors:  John Waugh; Blair Jarvis
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.